Abstract

Purpose: Simvastatin (SIM), a HMG-CoA reductase inhibitor widely prescribed for hypercholesterolemia, has been reported to ameliorate inflammation and promote osteogenesis. Its clinical applications on these potential secondary indications, however, have been hampered by its lack of osteotropicity and poor water solubility. To address this challenge, we propose to design and evaluate the therapeutic efficacy of a novel simvastatin prodrug with better water solubility and bone affinity. Method: The prodrug (SIM-PPi) was synthesized by directly conjugating a SIM trimer to a pyrophosphate (PPi). It was characterized and evaluated in vitro for its water solubility, osteotropicity, toxicity, anti-inflammatory and osteoinductive properties. It was then tested for anti-inflammatory and osteoinductive properties in vivo by three weekly injections into gingiva of a ligature-induced experimental periodontitis rat model. Results: In vitro studies showed that SIM-PPi has greatly improved water-solubility of SIM and shows strong binding to hydroxyapatite (HA). In macrophage culture, SIM-PPi inhibited LPS-induced pro-inflammatory cytokines (IL-1β, IL-6). In osteoblast culture, it was found to significantly increase alkaline phosphatase (ALP) activity with accelerated mineral deposition, confirming the osteogenic potential of SIM-PPi. When tested in vivo on an experimental periodontal bone-loss model, SIM-PPi exhibited a superior prophylactic effect compared to dose equivalent SIM in reducing inflammatory cells and in preserving alveolar bone structure, as shown in the histological and micro-CT data. Conclusion: SIM-PPi may have the potential to be further developed for better clinical management of bone loss associated with periodontitis.

Original languageEnglish (US)
Article number164
JournalPharmaceutical Research
Volume35
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Simvastatin
Periodontitis
Solubility
Bone
Water
Prodrugs
Cell culture
Bone and Bones
Anti-Inflammatory Agents
Alveolar Bone Loss
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Macrophages
Osteoblasts
Gingiva
Durapatite
Hypercholesterolemia
Interleukin-1
Osteogenesis
Minerals
Ligation

Keywords

  • periodontal bone loss
  • periodontitis
  • prodrug
  • pyrophosphate
  • simvastatin

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis. / Wang, Xiaobei; Jia, Zhenshan; Almoshari, Yosif; Lele, Subodh M; Reinhardt, Richard A; Wang, Dong.

In: Pharmaceutical Research, Vol. 35, No. 8, 164, 01.08.2018.

Research output: Contribution to journalArticle

@article{b777e067e1a64dd2a2c2b5e2d4544d94,
title = "Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis",
abstract = "Purpose: Simvastatin (SIM), a HMG-CoA reductase inhibitor widely prescribed for hypercholesterolemia, has been reported to ameliorate inflammation and promote osteogenesis. Its clinical applications on these potential secondary indications, however, have been hampered by its lack of osteotropicity and poor water solubility. To address this challenge, we propose to design and evaluate the therapeutic efficacy of a novel simvastatin prodrug with better water solubility and bone affinity. Method: The prodrug (SIM-PPi) was synthesized by directly conjugating a SIM trimer to a pyrophosphate (PPi). It was characterized and evaluated in vitro for its water solubility, osteotropicity, toxicity, anti-inflammatory and osteoinductive properties. It was then tested for anti-inflammatory and osteoinductive properties in vivo by three weekly injections into gingiva of a ligature-induced experimental periodontitis rat model. Results: In vitro studies showed that SIM-PPi has greatly improved water-solubility of SIM and shows strong binding to hydroxyapatite (HA). In macrophage culture, SIM-PPi inhibited LPS-induced pro-inflammatory cytokines (IL-1β, IL-6). In osteoblast culture, it was found to significantly increase alkaline phosphatase (ALP) activity with accelerated mineral deposition, confirming the osteogenic potential of SIM-PPi. When tested in vivo on an experimental periodontal bone-loss model, SIM-PPi exhibited a superior prophylactic effect compared to dose equivalent SIM in reducing inflammatory cells and in preserving alveolar bone structure, as shown in the histological and micro-CT data. Conclusion: SIM-PPi may have the potential to be further developed for better clinical management of bone loss associated with periodontitis.",
keywords = "periodontal bone loss, periodontitis, prodrug, pyrophosphate, simvastatin",
author = "Xiaobei Wang and Zhenshan Jia and Yosif Almoshari and Lele, {Subodh M} and Reinhardt, {Richard A} and Dong Wang",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s11095-018-2444-z",
language = "English (US)",
volume = "35",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis

AU - Wang, Xiaobei

AU - Jia, Zhenshan

AU - Almoshari, Yosif

AU - Lele, Subodh M

AU - Reinhardt, Richard A

AU - Wang, Dong

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: Simvastatin (SIM), a HMG-CoA reductase inhibitor widely prescribed for hypercholesterolemia, has been reported to ameliorate inflammation and promote osteogenesis. Its clinical applications on these potential secondary indications, however, have been hampered by its lack of osteotropicity and poor water solubility. To address this challenge, we propose to design and evaluate the therapeutic efficacy of a novel simvastatin prodrug with better water solubility and bone affinity. Method: The prodrug (SIM-PPi) was synthesized by directly conjugating a SIM trimer to a pyrophosphate (PPi). It was characterized and evaluated in vitro for its water solubility, osteotropicity, toxicity, anti-inflammatory and osteoinductive properties. It was then tested for anti-inflammatory and osteoinductive properties in vivo by three weekly injections into gingiva of a ligature-induced experimental periodontitis rat model. Results: In vitro studies showed that SIM-PPi has greatly improved water-solubility of SIM and shows strong binding to hydroxyapatite (HA). In macrophage culture, SIM-PPi inhibited LPS-induced pro-inflammatory cytokines (IL-1β, IL-6). In osteoblast culture, it was found to significantly increase alkaline phosphatase (ALP) activity with accelerated mineral deposition, confirming the osteogenic potential of SIM-PPi. When tested in vivo on an experimental periodontal bone-loss model, SIM-PPi exhibited a superior prophylactic effect compared to dose equivalent SIM in reducing inflammatory cells and in preserving alveolar bone structure, as shown in the histological and micro-CT data. Conclusion: SIM-PPi may have the potential to be further developed for better clinical management of bone loss associated with periodontitis.

AB - Purpose: Simvastatin (SIM), a HMG-CoA reductase inhibitor widely prescribed for hypercholesterolemia, has been reported to ameliorate inflammation and promote osteogenesis. Its clinical applications on these potential secondary indications, however, have been hampered by its lack of osteotropicity and poor water solubility. To address this challenge, we propose to design and evaluate the therapeutic efficacy of a novel simvastatin prodrug with better water solubility and bone affinity. Method: The prodrug (SIM-PPi) was synthesized by directly conjugating a SIM trimer to a pyrophosphate (PPi). It was characterized and evaluated in vitro for its water solubility, osteotropicity, toxicity, anti-inflammatory and osteoinductive properties. It was then tested for anti-inflammatory and osteoinductive properties in vivo by three weekly injections into gingiva of a ligature-induced experimental periodontitis rat model. Results: In vitro studies showed that SIM-PPi has greatly improved water-solubility of SIM and shows strong binding to hydroxyapatite (HA). In macrophage culture, SIM-PPi inhibited LPS-induced pro-inflammatory cytokines (IL-1β, IL-6). In osteoblast culture, it was found to significantly increase alkaline phosphatase (ALP) activity with accelerated mineral deposition, confirming the osteogenic potential of SIM-PPi. When tested in vivo on an experimental periodontal bone-loss model, SIM-PPi exhibited a superior prophylactic effect compared to dose equivalent SIM in reducing inflammatory cells and in preserving alveolar bone structure, as shown in the histological and micro-CT data. Conclusion: SIM-PPi may have the potential to be further developed for better clinical management of bone loss associated with periodontitis.

KW - periodontal bone loss

KW - periodontitis

KW - prodrug

KW - pyrophosphate

KW - simvastatin

UR - http://www.scopus.com/inward/record.url?scp=85049334642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049334642&partnerID=8YFLogxK

U2 - 10.1007/s11095-018-2444-z

DO - 10.1007/s11095-018-2444-z

M3 - Article

C2 - 29943090

AN - SCOPUS:85049334642

VL - 35

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 8

M1 - 164

ER -